NORLIQVA

PeakSM

amlodipine

NDAORALSOLUTION
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Calcium Channel Antagonists

Pharmacologic Class:

Dihydropyridine Calcium Channel Blocker

Clinical Trials (5)

NCT06236061Phase 3Completed

Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy

Started Apr 2024
718 enrolled
Hypertension
NCT03205137N/AWithdrawn

Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice

Started Jun 2022
0
Hypertension
NCT06713785Phase 4Withdrawn

Personalised Electronic Record Supported Optimisation of Amlodipine for Patients With Hypertension

Started Sep 2020
NCT03226275Phase 1Completed

Bioequivalence Trial of Concor AM® vs Bisoprolol and Amlodipine in Chinese Participants

Started Aug 2017
32 enrolled
Healthy
NCT02969265Phase 3Withdrawn

An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension

Started May 2017
0
Hypertension

Loss of Exclusivity

LOE Date
Feb 24, 2041
182 months away
Patent Expiry
Feb 24, 2041

Patent Records (5)

Patent #ExpiryTypeUse Code
11253474
Feb 24, 2041
Product
U-3311
11458095
Feb 24, 2041
Product
U-3311
11723866
Feb 24, 2041
Product
U-3310
12005141
Feb 24, 2041
Product
U-3310
12226528
Feb 24, 2041
Product
U-3311